Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Icatibant Use During Pregnancy: A South African Case Series.

Journal of investigational allergology & clinical immunology·2025
Same author

Imagining Futures: Evaluation of a blended programme of dialectical behaviour therapy and the creative arts for young women with a history of self-harm.

The British journal of clinical psychology·2025
Same author

Percutaneous balloon angioplasty as a treatment for cor triatriatum sinister in a cat.

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology·2024
Same author

Acute angioedema in Cape Town emergency centres and a suggested algorithm to simplify and improve management.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2023
Same author

The impact of COVID-19 public health measures on attendance and overdose at supervised injecting facilities in Australia.

Public health·2023
Same author

Self-reported beta-lactam allergy in government and private hospitals in Cape Town, South Africa.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2023
Same journal

The Upfront Effectiveness of a 6-Week Continuous Glucose Monitoring Intervention for Non-Insulin-Using Individuals With Type 2 Diabetes Is No Longer Detectable at 6-12 Months: An Observational Follow-Up of a Randomized Trial Cohort.

Diabetes, obesity & metabolism·2026
Same journal

Modelling the Clinical and Complication-Related Economic Burden of Therapeutic Inertia in People With Type 2 Diabetes in China.

Diabetes, obesity & metabolism·2026
Same journal

Hypoglycaemia Was Not Associated With Depression, Anxiety, Diabetes Distress or Fear of Hypoglycaemia Scores in People With Type 1 or Insulin-Treated Type 2 Diabetes in the Hypo-METRICS Study.

Diabetes, obesity & metabolism·2026
Same journal

Pubertal Stage-Based One-hour Postload Glucose Thresholds Improve Identification of Prediabetes and Type 2 Diabetes in Children With Overweight or Obesity.

Diabetes, obesity & metabolism·2026
Same journal

GLP-1-Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes.

Diabetes, obesity & metabolism·2026
Same journal

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study.

Diabetes, obesity & metabolism·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Fixed-dose single tablet antidiabetic combinations.

C J Bailey1, C Day

  • 1School of Life and Health Sciences, Aston University, Birmingham, UK. c.j.bailey@aston.ac.uk

Diabetes, Obesity & Metabolism
|January 30, 2009
PubMed
Summary
This summary is machine-generated.

Fixed-dose single tablet combinations for type 2 diabetes management offer convenience and improve patient adherence compared to separate pills. These combinations, like metformin with other agents, provide similar efficacy and require the same precautions.

Related Experiment Videos

Last Updated: Jun 26, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Area of Science:

  • Endocrinology
  • Pharmacology
  • Internal Medicine

Background:

  • Type 2 diabetes management frequently involves combining oral agents with distinct mechanisms to control hyperglycemia.
  • Historically, these combinations were administered as separate tablets, posing challenges in patient adherence and regimen complexity.
  • The advent of fixed-dose single tablet combinations (FDCs) presents a significant advancement in oral antihyperglycemic therapy.

Purpose of the Study:

  • To review the role and benefits of fixed-dose single tablet combinations in managing type 2 diabetes.
  • To highlight the advantages of FDCs over separate oral antihyperglycemic agents.
  • To discuss currently available and potential future FDC options.

Main Methods:

  • Review of current literature and available fixed-dose combination products for type 2 diabetes.
  • Analysis of the pharmacokinetic and pharmacodynamic profiles of FDCs in relation to their individual components.
  • Assessment of clinical outcomes, focusing on patient adherence and glycemic control.

Main Results:

  • Fixed-dose single tablet combinations are bioequivalent to their separate tablet counterparts, offering comparable efficacy.
  • FDCs significantly enhance patient convenience, reduce pill burden, and simplify medication regimens.
  • Improved patient adherence with FDCs is associated with better glycemic control compared to separate tablet regimens.

Conclusions:

  • Fixed-dose single tablet combinations represent a valuable therapeutic option for type 2 diabetes, improving adherence and potentially glycemic control.
  • Available FDCs include metformin combined with sulfonylureas, thiazolidinediones, DPP-4 inhibitors, or meglitinides, with various dosage strengths.
  • The trend towards multiple drug regimens suggests an increasing utilization of FDCs in future diabetes management strategies.